siParadigm diagnostic informatics

PR 888-782-5430 / 866-369-4114

USA 888-599-5227 / 201-599-9044 / 201-599-9066 / 888-890-4774 (Toll-free fax)

Requisition Number: _____

Pick-up Confirmation # _____

☐ RUSH ☐ Call Results ☐ Need Results by: ____ / ____ / ____

SOLID TUMOR REQUISITION FORM

PATIENT INFORMATION (REQUIRED)

Name Last _____ First _____

Date of Birth ____ (mm) / ____ (dd) / ____ (yyyy)

Street _____

City _____ State _____ ZIP _____

MRN / Patient ID# _____

Phone# _____

Fill in Mandatory Data at the Back of the Page

PHYSICIAN INFORMATION (REQUIRED)

Referring MD _____

Attending/Ordering MD _____

Account Information _____

SPECIMEN INFORMATION-TISSUE BIOPSY (REQUIRED)

Specimen ID _____ Block ID _____

Retrieval date from archive ____ (mm) / ____ (dd) / ____ (yyyy) Sent date ____ (mm) / ____ (dd) / ____ (yyyy)

Collection date ____ (mm) / ____ (dd) / ____ (yyyy) Time _____ ☐ AM ☐ PM

☐ Primary ☐ Metastatic If Metastatic, List primary _____

☐ Slides # _____ Unstained _____ Stained _____ ☐ H&E _____

☐ Paraffin Block(S) # _____ ☐ Peripheral Blood _____

☐ Choose best block

For global molecular/NGS testing only. Submit ≤4 FPPE blocks. Blocks will be combined for molecular testing when necessary.

A pathology report is **essential**

For packaging conditions and the required specimen quantity per test, please check our website:
https://www.siparadigm.com/physician-support/specimen-requirements

BILLING INFORMATION (BOTH SIDES REQUIRED)

☐ Insurance
☐ Client
☐ Patient

SPECIMEN COLLECTION LOCATION

☐ Non-hospital/office patient
☐ Out-patient hospital
☐ In-patient hospital Discharge Date ____ (mm) / ____ (dd) / ____ (yyyy)

ICD-10 CODE _____

SPECIMEN INFORMATION-LIQUID BIOPSY (OPTIONAL)

Specimen ID _____

Collection date ____ (mm) / ____ (dd) / ____ (yyyy) Time _____ ☐ AM ☐ PM

Sent date ____ (mm) / ____ (dd) / ____ (yyyy)

A pathology report is **required**

PAXgene (blue top) specimen collection tubes and DeepSight collection kits must be utilized. Preferred minimum blood volume: >20-30 ml. For additional details, please visit our website.

THIRD-PARTY SPECIMEN LOCATION (REQUIRED)

Hospital/Facility _____ Phone # _____

Address _____

Fax # _____

MOBILE PHLEBOTOMY REQUEST (ONCOLOGY OFFICE TO COMPLETE IF NEEDED)

Patient Phone (mobile preferred): _____

Patient Email (optional): _____

Patient Home Address: _____

City, ST, ZIP: _____

siParadigm Liquid Biopsy collection and shipping kit was provided to the patient. Please fax this completed requisition, pathology report, and insurance information to 888-890-4774

By completing this section, Client represents it has obtained patient's consent to be contacted by third-party service.

CLINICAL INFORMATION (REQUIRED)

CANCER TYPE

☐ Bladder ☐ Colorectal ☐ Lung ☐ Ovarian ☐ Thyroid ☐ Prostate
☐ Brain ☐ Endometrial ☐ GI, Upper ☐ Melanoma ☐ Breast
☐ Others _____

NOTES

Attach clinical notes, pathology reports and insurance card (s)

SIGNATURE

I certify that the services requested are medically necessary and will assist in treating my patient, and I will make available patient medical records documenting the foregoing. I also understand that an Advance Beneficiary Notice of Non-coverage (ABN) may be required if the ICD-10 codes or the provided medical records may not be supported by Medicare and Medicaid.

AUTHORIZED SIGNATURE _____ DATE _____

CONCURRENT TISSUE AND LIQUID TESTING OPTIONS

☐ siPortfolio Multi-Omics™ on Tissue + DeepSight™ on Liquid

TAT 7-10 Days

- **On Tissue:**
  - NGS (500+ genes, TMB, MSI)
  - HRD for PARPi therapy
  - IHC, FISH (as clinically pertinent and necessary)
- **On Liquid:** DeepSight™ Comprehensive Liquid Biopsy (523 genes mutations and fusions)

***Please use Liquid Biopsy DeepSight™ kit for blood specimen collection**

☐ NGS 500-Genes on Tissue + DeepSight™ on Liquid

TAT 7-10 Days

- **On Tissue:**
  - NGS (500+ genes, TMB, MSI)
  - HRD for PARPi therapy
- **On Liquid:** DeepSight™ Comprehensive Liquid Biopsy (523 genes mutations and fusions)

***Please use Liquid Biopsy DeepSight™ kit for blood specimen collection**

TISSUE ONLY TESTING OPTIONS

☐ siPortfolio, Multi-Omics™

Includes:

- NGS (500+ genes,TMB, MSI)
- HRD for PARPi therapy
- IHC, FISH
- Specimen:FFPE

☐ OPTIONAL Blood (lavender tube) for germline HRD testing

TAT ≤ 7-10 Days

☐ LymphoSight™

Complete Consult: Accurately curated by our expert board-certified hematopathologists, this comprehensive offering selects medically necessary tests—Flow, IHC, FISH, and Molecular assays—based on patient diagnosis, prior test findings, and clinical history, ensuring thorough evaluation and consultation for complex lymphoma cases.

TAT 7-10 Days

☐ OncoSwift® 50 → 500 Comprehensive

The analysis is limited to 50 gene set +TMB, MSI, and LOH, in case genomic alterations of strong clinical evidence are detected

OncoSwift® Prelim Report (50 genes): TAT ≤ 4-5 Days

OncoSwift® Final Report (500 genes): TAT ≤ 7-10 Days

☐ Oncoswift® Frontier

Testing is limited to 50 gene set + TMB, MSI, and LOH in the event that Tier 1 (Strong Clinical Significance) genomic alterations are detected. HRR gene coverage is limited, Oncoswift® Frontier is therefore not appropriate for PARPi therapy prediction or testing in gynecologic neoplasms, pancreatic, or prostatic adenocarcinomass

Oncoswift® Frontier Report (50 genes): TAT ≤ 4-5 Days

☐ NGS 500-Genes

Includes:

- NGS (500+ genes,TMB, MSI)
- HRD for PARPi therapy
- Specimen:FFPE

☐ OPTIONAL Blood (lavender tube) for germline HRD testing

TAT ≤ 7-10 Days

☐ NGS 50-Genes

Includes:

- NYS-approved
- 50 gene, targeted NGS panel inclusive of NTRK1/2/3, for more targeted analysis and rapid results
- Rare mutations, HRD, TMB, MSI, not included
- Specimen: FFPE

TAT 4-5 Days

REFLEX TESTING OPTIONS

☐ Reflex Tissue to Liquid

If the tissue is insufficient or unattainable in 5 working days reflex to DeepSight™ Comprehensive 523 genes liquid biopsy testing on liquid

☐ Reflex Liquid to Tissue

If liquid biopsy is negative or QNS reflex to siPortfolio Multi-Omics™ 500 genes testing on tissue

INDIVIDUAL GENE TESTING – (ONLY AVAILABLE ON TISSUE)

Immunohistochemistry (IHC)

☐ ALK, D5F3, FDA
☐ BRAF
☐ Breast IHC biomarkers (whole panel) ER PgR Her2/neu Ki67
☐ ER
☐ Folate Receptor Alpha
☐ Her2/neu,FDA
☐ Her2 FISH reflex, if Her2 IHC equivocal
☐ Ki67
☐ MMR (MLH1, MSH2, MSH6 & PMS2)
☐ TP53
☐ PD-L1, 22C3, FDA (KEYTRUDA®)
☐ PD-L1, 28-8, FDA (OPDIVO®)
☐ PD-L1, SP263, FDA (IMFINZI®)
☐ PD-L1, SP142, FDA (TECENTRIQ®)
☐ PgR
☐ ROS1

FISH

☐ 1p/19q Deletion
☐ ALK,FDA
☐ HER2/neu FDA
☐ MET
☐ PTEN Deletion
☐ RET
☐ ROS1
☐ UroVysion,FDA (use special container)

MOLECULAR

☐ Androgen Receptor (AR)
☐ BRAF (incl. V600)
☐ BRCA1&2 for PARP inhibitors efficacy (FFPE and/or blood required)
☐ c-ERBB2 (HER-2/neu)
☐ EGFR
☐ IDH1/IDH2
☐ KRAS (12,13,61,117 & 146)
☐ MGMT Promoter Methylation
☐ MSI by NGS (TAT 7-10 days)
☐ NRAS (exons 2,3 & 4)
☐ PTEN
☐ RB1
☐ TP53
☐ Other

siParadigm diagnostic informatics

PR 888-782-5430
866-369-4114

USA 888-599-5227 / 201-599-9044
201-599-9066
888-890-4774 (Toll-free fax)

Requisition Number

Pick-up Confirmation #

ADDITIONAL INFORMATION (REQUIRED)

Gender Identity: ☐ Male ☐ Female ☐ Female-to-Male (FTM)/Transgender Male/Trans Man ☐ Male-to-Female (MTF)/Transgender Female/Trans Woman ☐ Genderqueer, neither exclusively male nor female ☐ Additional gender category or other, please specify _____ ☐ Choose not to disclose

Ethnicity

☐ African-American ☐ Jewish-Ashkenazi ☐ Adopted ☐ Asian ☐ Caucasian/NW European ☐ Jewish-Sephardic ☐ Native American ☐ Hispanic ☐ Middle Eastern ☐ Unknown ☐ Asked but Unknown ☐ Non-Hispanic or Non-Latino ☐ Other _____ ☐ Choose not to disclose

Sexual Orientation: ☐ Lesbian, gay, or homosexual ☐ Straight or heterosexual ☐ Bisexual ☐ Don't know ☐ Something else, please describe _____ ☐ Choose not to disclose

Race: ☐ American Indian or Alaska Native ☐ Black or African American ☐ White ☐ Native Hawaiian or Other Pacific Islander ☐ Asian ☐ Unknown ☐ Asked but Unknown ☐ Other _____ ☐ Choose not to disclose

500+ GENE TABLE

The following genes are interrogated for DNA level mutations (SNVs (single nucleotide variants), Indels (insertion-deletion events)), Tumor Mutation Burden (TMB), NGS based tumor-only Microsatellite Instability (MSI), and genome wide Loss of Heterozygosity (LOH). RNA level abnormalities and CNV information also listed below. Gene specific technical details are available upon request, e.g. transcript IDs, mutational hotspots, whole exonic coding regions, etc.

A1CF, ABCB1, ABL1, ABL2, ABRAXAS1, ACSM2B, ACVR1, ACVR1B, ACVR2A, ADAM18, ADAMTS12, ADAMTS2, AKT1, AKT2, AKT3, ALK, AMER1, ANO4, APC, AR, ARAF, ARHGAP35, ARID1A, ARID1B, ARID2, ARID5B, ARMC4, ASXL1, ASXL2, ATM, ATP1A1, ATR, ATRX, AURKA, AURKC, AXIN1, AXIN2, AXL, B2M, BAP1, BARD1, BCL2, BCL2L12, BCL6, BCOR, BCR, BLM, BMP5, BMPR2, BRAF, BRCA1, BRCA2, BRINP3, BRIP1, BTK, C6, C8A, C8B, CACNA1D, CALR, CANX, CARD11, CASP8, CASR, CBFB, CBL, CCND1, CCND2, CCND3, CCNE1, CD163, CD274, CD276, CD79B, CDC73, CDH1, CDH10, CDK12, CDK4, CDK6, CDKN1A, CDKN1B, CDKN2A, CDKN2B, CDKN2C, CHD4, CHEK1, CHEK2, CIC, CIITA, CNTN6, CNTNAP4, CNTNAP5, COL11A1, CREBBP, CSF1R, CSMD3, CTCF, CTLA4, CTNNB1, CTNND2, CUL1, CUL3, CUL4A, CUL4B, CYLD, CYP2C9, CYP2D6, CYSLTR2, DAXX, DCAF4L2, DCDC1, DDR1, DDR2, DDX3X, DGCR8, DICER1, DNMT3A, DOCK3, DPYD, DROSHA, DSC1, DSC3, E2F1, EGFR, EIF1AX, ELF3, EMSY, ENO1, EP300, EPAS1, EPCAM, EPHA2, ERAP1, ERAP2, ERBB2, ERBB3, ERBB4, ERCC2, ERCC4, ERCC5, ERRFI1, ESR1, ETV6, EZH2, FAM135B, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, FAS, FAT1, FBXW7, FGF19, FGF23, FGF3, FGF4, FGF7, FGF9, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, FLT4, FOXA1, FOXL2, FOXO1, FUBP1, FYN, GALNT17, GATA2, GATA3, GLI1, GLI3, GNA11, GNA13, GNAQ, GNAS, GPR158, GPS2, GRID2, H3F3A, H3F3B, HCN1, HDAC2, HDAC9, HIF1A, HIST1H2BD, HIST1H3B, HLA-A, HLA-B, HLA-C, HNF1A, HRAS, ID3, IDH1, IDH2, IGF1R, IKBKB, IL6ST, IL7R, INPP4B, IRF4, IRS4, JAK1, JAK2, JAK3, KCND2, KCNH7, KDM5C, KDM6A, KDR, KEAP1, KEL, KIR3DL1, KIT, KLF4, KLF5, KLHL13, KMT2A, KMT2B, KMT2C, KMT2D, KNSTRN, KRAS, KRTAP2-1, KRTAP6-2, LARP4B, LATS1, LATS2, LRRC7, MAGOH, MAP2K1, MAP2K2, MAP2K4, MAP2K7, MAP3K1, MAP3K4, MAPK1, MAPK8, MARCO, MAX, MCL1, MDM2, MDM4, MECOM, MED12, MEF2B, MEN1, MET, MGA, MITF, MLH1, MLH3, MPL, MRE11, MSH2, MSH3, MSH6, MTAP, MTOR, MTUS2, MUTYH, MYC, MYCL, MYCN, MYD88, MYOD1, NBN, NCOR1, NF1, NF2, NFE2L2, NLRC5, NOL4, NOTCH1, NOTCH2, NOTCH3, NOTCH4, NRAS, NRXN1, NSD2, NT5C2, NTRK1, NTRK2, NTRK3, NUP93, NYAP2, OR10G8, OR2G6, OR2L13, OR2L2, OR2L8, OR2M3, OR2T3, OR2T33, OR2T4, OR2W3, OR4A15, OR4C15, OR4C6, OR4M1, OR4M2, OR5D18, OR5F1, OR5L1, OR5L2, OR6F1, OR8H2, OR8I2, OR8U1, ORC4, PAK5, PALB2, PARP1, PARP2, PARP3, PARP4, PAX5, PBRM1, PCBP1, PCDH17, PDCD1, PDCD1LG2, PDE1A, PDE1C, PDGFRA, PDGFRB, PDIA3, PGD, PHF6, PIK3C2B, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PIK3R1, PIK3R2, PIM1, PLCG1, PLXDC2, PMS1, PMS2, POLD1, POLE, POM121L12, POT1, PPFIA2, PMS1, PMS2, POLD1, POLE, POM121L12, POT1, PPFIA2, PPM1D, PPP2R1A, PPP2R2A, PPP6C, PRDM1, PRDM9, PRKACA, PRKAR1A, PSMB10, PSMB8, PSMB9, PTCH1, PTEN, PTPN11, PTPRD, PTPRT, PXDNL, RAC1, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD52, RAD54L, RAF1, RARA, RASA1, RASA2, RB1, RBM10, RBP3, RECQL4, REG1A, REG1B, REG3A, REG3G, RET, RGS7, RHEB, RHOA, RICTOR, RIT1, RNASEH2A, RNASEH2B, RNASEH2C, RNF43, ROS1, RPA1, RPL10, RPL22, RPL5, RPS6KB1, RPTN, RPTOR, RUNDC3B, RUNX1, RUNX1T1, SDHA, SDHB, SDHC, SDHD, SETBP1, SETD2, SF3B1, SH3RF2, SIX1, SIX2, SLC15A2, SLC8A1, SLCO1B3, SLX4, SMAD2, SMAD4, SMARCA4, SMARCB1, SMC1A, SMO, SNCAIP, SOCS1, SOS1, SOX2, SOX9, SPEN, SPOP, SRC, SRSF2, STAG2, STAT1, STAT3, STAT5B, STAT6, STK11, SUFU, SYT10, SYT16, TAF1, TAP1, TAP2, TAPBP, TBX3, TCF7L2, TERT, TET2, TGFBR1, TGFBR2, TMEM132D, TNFAIP3, TNFRSF14, TOP1, TP53, TP63, TPMT, TPP2, TPTE, TRHDE, TRIM48, TRIM51, TRRAP, TSC1, TSC2, TSHR, U2AF1, UGT1A1, USP8, USP9X, VHL, WAS, WT1, XPO1, XRCC2, XRCC3, YAP1, YES1, ZBTB20, ZFHX3, ZIM3, ZMYM3, ZNF217, ZNF429, ZNF479, ZNF536, ZRSR2

The following RNA level gene fusions and abnormal splice isoforms are interrogated:

ABL1, ALK, AKT3, AR-V7, AXL, BRAF, EGFR, EGFR vIII, ERBB2, ERG, ETV1, ETV4, ETV5, FGFR1, FGFR2, FGFR3, MET, MET exon 14 skipping, NTRK1, NTRK2, NTRK3, PDGFRA, PPARG, RAF1, RET, ROS1

Homologous Recombination Repair (HRR) *genes included in 500 gene panel:*

A1CF, ABCB1, ABL1, ABL2, ABRAXAS1, ATM, ATR, BAP1, BARD1, BLM, BRCA1, BRCA2, BRIP1, CDK12, CHEK1, CHEK2, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, MRE11, NBN, PALB2, PARP1, PARP2, PARP3, POLD1, POLE, PPP2R2A, PTEN, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD52, RAD54L, RNASEH2A, RNASEH2B, RNASEH2C, RPA1, SLX4, XRCC2, XRCC3

CNV

ALK, AR, CD274, CDKN2A, EGFR, ERBB2, ERBB3, FGFR1, FGFR2, FGFR3, KRAS, MET, PIK3CA, PTEN

50 GENE TABLE

DNA Hotspots

AKT1, AKT2, AKT3, ALK, AR, ARAF, BRAF, CDK4, CDKN2A, CHEK2, CTNNB1, EGFR, ERBB2, ERBB3, ERBB4, ESR1, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, GNA11, GNAQ, GNAS, HRAS, IDH1, IDH2, KIT, KRAS, MAP2K1, MAP2K2, MET, MTOR, NRAS, NTRK1, NTRK2, NTRK3, PDGFRA, PIK3CA, PTEN, RAF1, RET1, ROS1, SMO, TP53

CNV

ALK, AR, CD274, CDKN2A, EGFR, ERBB2, ERBB3, FGFR1, FGFR2, FGFR3, KRAS, MET, PIK3CA, PTEN

RNA level gene fusions

ALK, BRAF, ESR1,FGFR1, FGFR2, FGFR3, MET, NRG1, NTRK1, NTRK2, NTRK3, NUTM1, RET, ROS1, RSPO2, RSPO3

Abnormal RNA Splice Isoforms

AR-V7, EGFR vIII, MET exon 14 skipping

25 Riverside Drive, Suite #2, Pine Brook, NJ 07058
www.siparadigm.com

CLIA CERTIFIED

cap ACCREDITED™